` EPE (Epizyme Inc) vs DAX Index Comparison - Alpha Spread

EPE
vs
DAX Index

Over the past 12 months, EPE has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's 10% growth.

Stocks Performance
EPE vs DAX Index

Loading

Performance Gap
EPE vs DAX Index

Loading
EPE
DAX Index
Difference

Performance By Year
EPE vs DAX Index

Loading
EPE
DAX Index
Add Stock

Competitors Performance
Epizyme Inc vs Peers

DAX Index
EPE
ABBV
AMGN
GILD
VRTX
Add Stock

Epizyme Inc
Glance View

Economic Moat
None
Market Cap
94.1B EUR
Industry
Biotechnology

Nestled in the bustling world of biotechnology, Epizyme Inc. emerged as a dynamic player within the realm of epigenetic medicine. The company carved a niche for itself by focusing on the development and commercialization of novel therapeutics that target the epigenetic regulation of gene expression. Founded with a vision to harness the power of small molecules to modulate the proteins responsible for reading and interpreting the epigenetic code, Epizyme strives to innovate therapies that can treat patients with serious unmet medical conditions, particularly in oncology. Its flagship product, Tazemetostat, received FDA approval for the treatment of certain types of lymphoma and soft tissue sarcoma. This marked a significant milestone for the company, confirming its ability to transform complex biological science into tangible, market-ready solutions. With a strategic approach centered on precision medicine, Epizyme monetizes its innovations primarily through direct sales, partnerships, and licensing agreements. The company’s revenue streams are buoyed by its collaborations with other biotechnology and pharmaceutical companies keen on leveraging Epizyme’s specialized expertise to advance their own drug development programs. Moreover, by advancing a robust pipeline of epigenetic therapies that span a variety of therapeutic areas, Epizyme positions itself to capture a growing share of the biotechnology market. Intellectual property and sophisticated R&D capabilities underpin its business model, enabling the company not only to produce groundbreaking therapies but also to secure significant market opportunities in an increasingly competitive landscape.

EPE Intrinsic Value
Not Available
E
Back to Top